Related Experiment Video

Updated: Jul 2, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer

Wen-Chin Huang1, Jonathan J Havel, Haiyen E Zhau

  • 1Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, GA 30322, USA. whuang3@emory.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 4, 2008
PubMed
Abstract

Insights

Targeting beta2-Microglobulin (beta2M) with an antibody inhibits prostate cancer cell growth and induces apoptosis by down-regulating the androgen receptor (AR) or directly. This antibody shows promise for treating prostate cancer.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Beta-2-microglobulin (beta2M) is implicated in prostate cancer osteomimicry and proliferation.
  • Understanding beta2M's role is crucial for developing targeted therapies.

Purpose of the Study:

  • To elucidate the mechanism by which anti-beta2M antibodies inhibit prostate cancer cell growth and induce apoptosis.
  • To investigate beta2M's role in androgen receptor (AR) signaling.

Main Methods:

  • Utilized polyclonal and monoclonal beta2M antibodies in human prostate cancer cell lines and mouse xenografts.
  • Assessed the impact of beta2M antibody on AR and prostate-specific antigen (PSA) expression.
  • Investigated effects on both AR-positive and AR-negative prostate cancer cells.

Main Results:

  • Beta2M antibody inhibited growth and induced apoptosis in both AR-positive and AR-negative prostate cancer cells.
  • Mechanism involved AR down-regulation in AR-positive cells and direct apoptosis induction in AR-negative cells.
  • No effect observed on normal prostate cells' AR expression or growth.

Conclusions:

  • Beta2M signaling directly influences AR and PSA expression in AR-positive prostate cancer.
  • Interrupting beta2M signaling effectively inhibits cancer cell proliferation and induces apoptosis.
  • Anti-beta2M antibody represents a potential novel therapeutic for prostate cancer.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...